The Chicago Board Options Exchange (Cboe) has filed to list a staked Injective ETF from Canary Capital and is making new inroads in digital assets. This fund was filed through Form 19b-4 in America. The Securities and Exchange Commission (SEC) recently approved the second altcoin ETF. Now, the SEC could soon approve a staked altcoin ETF in the country.
Canary Capital’s S-1 filing with the SEC made on July 17 seeks staking rewards from participation in blockchain validation through the regulated staking platform behind the fund. If it gets approved, the fund would offer investors prime exposure to Injective’s governance token while earning yield from staking — one of the most requested features among crypto-savvy investors and institutions.
The timing of this filing is notable. With the current U.S. administration, crypto regulation seems to be progressing toward a more pro-innovation approach centered around regulated digital asset products. Although the SEC has not filed a response yet, they will acknowledge the filing in early September. Depending on the deliberations of regulators, the review will not extend beyond March 2026.
In May 2025, the SEC clarified that staking is not a violation of securities laws, providing a significant regulatory breakthrough. Industry leaders hailed this move as a landmark decision. Alison Mangiero, who is working on staking policy at the Crypto Council for Innovation, said:
The SEC recognizes that staking is part of the operations of modern blockchains, and so it is not a security. It is important to innovate because of clarification.
The approval of the Injective ETF would boost the price of the INJ token. Currently, the value of INJ token was $15.10. It is still far from the all-time high of $52 that was recorded in March 2024. An approval would help inject a fresh wind into the token.
This mirrors what was seen with Bitcoin-based ETFs, which accounted for more than three-quarters of BTC inflows as the asset surged over $50,000 in early 2024. Things were somewhat different for Ethereum ETFs, as Ether slumped over 38% in the two weeks post-launch, likely affected by heavy outflows from Grayscale’s ETHE fund.
More and more investors are keen on these ETFs. Items like the suggested Injective ETF show how the focus of institutions is shifting from price speculation to yield-generating crypto strategies — a shift that aligns with the utility and development of blockchain networks.
Conclusion
Cboe’s recent listing of Canary Capital’s Injective ETF containing a staked asset reflects a growing maturity of regulated crypto investment products. As U.S. regulators get clearer on their guidance and institutions seek yield-form products, staking-focused ETFs such as these could usher in the next wave of mainstream crypto adoption.
